Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.
Alentis Therapeutics has raised €11M across 1 funding round from 2 investors, most recently a Series A round in Apr 2019. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-04-01 | Series A |
| €11M |
| BioMedPartners,Pureos Bioventures |
| View deal → |
